Skip to main content

News

The latest news, stories, and updates from the Children's Tumor Foundation.

 

Filter

Cover of the 2024 Impact Report by Children's Tumor Foundation, featuring a blue molecular structure with the text "Accelerating Discovery, Transforming Lives.
AwarenessFeaturedFeatured EU

Children’s Tumor Foundation 2024 Impact Report

The Children’s Tumor Foundation (CTF) has released its latest impact report, detailing significant progress in…
A person with short hair, glasses, and a black jacket smiles against a dark background.
FeaturedFeatured EUScience & Research

CTF CEO Annette Bakker Moderates Panel at World Orphan Drug Congress 2025

Children’s Tumor Foundation CEO Annette Bakker to speak on unleashing the life-changing potential of shelved…
A group of laboratory glassware, including beakers and flasks, is arranged on a reflective surface with a blue light in the background.
CTF in the NewsFeaturedFeatured EUScience & Research

How a Once-Abandoned Drug Found New Life – and Changed the Future for NF Patients

The drug mirdametinib was once shelved by Pfizer. Today, it’s Gomekli - an FDA-approved treatment…
A woman speaks at a podium during the Global NF Conference, with text highlighting "Patient Day at the Global NF Conference" on a blue background.
GlobalNF Conference

Patient Day at the Global NF Conference

As part of the 2024 Global NF Conference, the Children’s Tumor Foundation hosted its second…
A person with long wavy hair, wearing a black and white checkered blazer and a white shirt, against a gray background.
Awards & GrantsFeaturedFeatured EUNF1Science & Research

Young Investigator: Q&A with Sarah Morrow about NF1 and MPNST

The Young Investigator Award (YIA) provides two-year salary support to early-career NF researchers to help…
The United States Capitol building with its large dome and columns is shown from the front. An American flag waves on top, under a clear blue sky.
AdvocacyFeaturedFeatured EU

Children’s Tumor Foundation Chair Pens Message Urging Restoration of NF Research Funding

In an op-ed published in RealClearHealth, Gabriel Groisman, Chair of the Children's Tumor Foundation, calls…
A person stands with arms crossed next to text announcing their joining CureAge Therapeutics from the Children's Tumor Foundation. Logos of both organizations are displayed.
Collaborations & PartnershipsGlobalPress Release

Children’s Tumor Foundation’s Montse Montaner Joins CureAge Therapeutics

Seasoned international advisor will serve on the board of CureAge Therapeutics The Children's Tumor Foundation…
Children's Tumor Foundation logo on the left and Rare Disease Day logo with February 28 date on the right.
AdvocacyAwarenessFeaturedFeatured EUPharma

From NF to the World: Rare Disease Day and the Race for Faster Treatments

This has been a February to remember! In just a few weeks, a new drug…
Collaborations & PartnershipsFeaturedFeatured EUNF1PharmaPress ReleaseScience & Research

Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of NF1

Healx has dosed the first patient in its Phase 2 trial for HLX-1502 - the…
Tri-fold brochure for Children's Tumor Foundation Europe, detailing NF information, mission, and contact details. Features images of smiling people and foundation's logo.
Featured EU

CTF Europe Brochure in Multiple Languages

We are pleased to share our new trifold brochure about CTF Europe, now available in…
Three people smiling and posing in front of a banner for the 2024 Global Conference, held in Brussels from June 20-25, 2024.
Collaborations & PartnershipsFeaturedFeatured EUNF1PharmaPress ReleaseScience & Research

CureAge Therapeutics Launches to Advance Genetic Therapies for Neurofibromatosis

Children’s Tumor Foundation and Deep Science Ventures Spearhead New Biotech to Develop Curative Treatments for…
Child cheering beside text: "IT'S A GO! FDA approves drug for children and adults with NF1." Website: ctf.org.
NF1PharmaScience & ResearchTop StoryTop Story EU

IT’S A GO! NF’s NEXT BIG WIN!

Today, we make history... again! The FDA has officially approved Gomekli (mirdametinib) - the second-ever…